Surgical Research Unit, Department of Surgery, Geneva University Hospital and University of Geneva, Geneva, Switzerland.
PLoS One. 2011;6(9):e25442. doi: 10.1371/journal.pone.0025442. Epub 2011 Sep 27.
Cytokine administration is a potential therapy for acute liver failure by reducing inflammatory responses and favour hepatocyte regeneration. The aim of this study was to evaluate the role of interleukin-1 receptor antagonist (IL-1ra) during liver regeneration and to study the effect of a recombinant human IL-1ra on liver regeneration.
We performed 70%-hepatectomy in wild type (WT) mice, IL-1ra knock-out (KO) mice and in WT mice treated by anakinra. We analyzed liver regeneration at regular intervals by measuring the blood levels of cytokines, the hepatocyte proliferation by bromodeoxyuridin (BrdU) incorporation, proliferating cell nuclear antigen (PCNA) and Cyclin D1 expression. The effect of anakinra on hepatocyte proliferation was also tested in vitro using human hepatocytes.
At 24h and at 48 h after hepatectomy, IL-1ra KO mice had significantly higher levels of pro-inflammatory cytokines (IL-6, IL-1β and MCP-1) and a reduced and delayed hepatocyte proliferation measured by BrdU incorporation, PCNA and Cyclin D1 protein levels, when compared to WT mice. IGFBP-1 and C/EBPβ expression was significantly decreased in IL-1ra KO compared to WT mice. WT mice treated with anakinra showed significantly decreased levels of IL-6 and significantly higher hepatocyte proliferation at 24h compared to untreated WT mice. In vitro, primary human hepatocytes treated with anakinra showed significantly higher proliferation at 24h compared to hepatocytes without treatment.
IL1ra modulates the early phase of liver regeneration by decreasing the inflammatory stress and accelerating the entry of hepatocytes in proliferation. IL1ra might be a therapeutic target to improve hepatocyte proliferation.
细胞因子治疗通过减轻炎症反应和促进肝细胞再生,是急性肝衰竭的一种潜在治疗方法。本研究旨在评估白细胞介素-1 受体拮抗剂(IL-1ra)在肝再生过程中的作用,并研究重组人 IL-1ra 对肝再生的影响。
我们在野生型(WT)小鼠、IL-1ra 敲除(KO)小鼠和接受 anakinra 治疗的 WT 小鼠中进行了 70%肝切除术。我们通过测量细胞因子的血液水平、溴脱氧尿苷(BrdU)掺入、增殖细胞核抗原(PCNA)和细胞周期蛋白 D1 表达来定期分析肝再生。还在体外用人肝细胞测试了 anakinra 对肝细胞增殖的影响。
肝切除后 24 小时和 48 小时,与 WT 小鼠相比,IL-1ra KO 小鼠的促炎细胞因子(IL-6、IL-1β 和 MCP-1)水平明显更高,BrdU 掺入、PCNA 和细胞周期蛋白 D1 蛋白水平的肝细胞增殖减少且延迟。与 WT 小鼠相比,IL-1ra KO 小鼠的 IGFBP-1 和 C/EBPβ 表达明显降低。与未治疗的 WT 小鼠相比,用 anakinra 治疗的 WT 小鼠在 24 小时时显示出 IL-6 水平明显降低,且肝细胞增殖明显增加。在体外,与未经处理的肝细胞相比,用 anakinra 处理的原代人肝细胞在 24 小时时显示出明显更高的增殖率。
IL-1ra 通过降低炎症应激和加速肝细胞进入增殖来调节肝再生的早期阶段。IL-1ra 可能是改善肝细胞增殖的治疗靶点。